Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kolon Life Science Inc. has 2 pending office actions currently active in the Biotechnology & Pharmaceuticals technology area. These matters are both located within 1 distinct art unit, which suggests a high degree of technical consistency in the company's current filings. Despite being in the same art unit, the cases are assigned to 2 distinct examiners, introducing different individual perspectives into the prosecution process. This structure allows the applicant to benefit from a consistent art unit policy while navigating the specific preferences of multiple officials.
The busiest examiner, RAHMAN, MASUDUR, is responsible for 1 pending office action. With the total workload split between the assigned examiners, the company can observe how different individuals within the same art unit interpret their biotechnology claims. This can provide valuable insights for future filing strategies and help refine the approach to claim drafting. Focusing on a single distinct art unit simplifies the high-level legal research required, as the general practices of that unit will apply to both pending matters.
However, the use of multiple examiners means that practitioners must still tailor their responses to individual preferences. The pending office actions represent a concentrated but multi-perspective engagement with the patent office's life sciences division. Success in this 1 distinct art unit will depend on the ability to reconcile the feedback from RAHMAN, MASUDUR with the requirements of the other assigned examiner. This balanced workload ensures that the company's Biotechnology & Pharmaceuticals innovations receive thorough and varied scrutiny.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMAN, MASUDUR | 1 | 72.7% | +31.7% |
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18281412 | COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES | RAHMAN, MASUDUR | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18281412 | COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES | RAHMAN, MASUDUR | 21d |
| 16963046 | RECOMBINANT VACCINIA VIRUS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SPENCE, JENNIFER SUZANNE | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18281412 | COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES | RAHMAN, MASUDUR | 1633 | §102§103 | Non-Final OA | 21d | Pending | Sep 11, 2023 |
| 16963046 | RECOMBINANT VACCINIA VIRUS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SPENCE, JENNIFER SUZANNE | 1633 | §103 | Non-Final OA | — | Pending | Jul 17, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial